Trials / Completed
CompletedNCT04914767
Nigella 5 in the Treatment of SARS COV2 (COVID-19)
The Effectiveness of Nigella Sativa in the Treatment of SARS COV2 (COVID-19)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 500 (actual)
- Sponsor
- Hôpital Universitaire Sahloul · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The world is currently facing a crisis because of this potentially fatal situation of the COVID-19 epidemic without proven efficacy for any drug treatment, while the vaccination is not yet. This epidemic is caused by a new betacorona virus, now called SARS-CoV-2. The most common symptoms reported are fever, cough or chest tightness, and dyspnea. Most cases have a mild course
Detailed description
In the absence of proven antiviral therapy or specific vaccination against COVID-19, Nigella seed oil is suggested as a potential supplement due to its known immunostimulatory and antiviral activities in previous published studies. Nigella (known as black seed) in the Latin language or "Habatulbarakah" in the Arabic language, is a food supplement and a medicinal plant well known in Arab and Islamic culture. It is used as a food spice and it has a lot of medical claims that come from different historical backgrounds. Nigella seeds contain several active compounds that have been isolated, identified and reported, the most important being thymoquinone. In the literature, black seed has shown several pharmacological activities, including anti-inflammatory, antiviral and immunostimulatory activities.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nigella | The patient will receive a study treatment containing 100 capsules: * One capsule every two hours for the first three days. * From the fourth day, the patient will take one capsule, three times a day for 12 days. |
| DRUG | Placebo | The patient will receive a study treatment containing 100 capsules: * One capsule every two hours for the first three days. * From the fourth day, the patient will take one capsule, three times a day for 12 days. |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2021-10-30
- Completion
- 2021-12-31
- First posted
- 2021-06-07
- Last updated
- 2022-02-21
Locations
2 sites across 1 country: Tunisia
Source: ClinicalTrials.gov record NCT04914767. Inclusion in this directory is not an endorsement.